The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)

Brian J. Druker

Oregon Health & Science University Knight Cancer Institute





Name/email consistency: high



  • Oregon Health & Science University Knight Cancer Institute, Portland, Oregon, USA. 2001 - 2009
  • Howard Hughes Medical Institute. 2004


  1. Perspectives on the development of imatinib and the future of cancer research. Druker, B.J. Nat. Med. (2009) [Pubmed]
  2. Translation of the Philadelphia chromosome into therapy for CML. Druker, B.J. Blood (2008) [Pubmed]
  3. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. Druker, B.J., Guilhot, F., O'Brien, S.G., Gathmann, I., Kantarjian, H., Gattermann, N., Deininger, M.W., Silver, R.T., Goldman, J.M., Stone, R.M., Cervantes, F., Hochhaus, A., Powell, B.L., Gabrilove, J.L., Rousselot, P., Reiffers, J., Cornelissen, J.J., Hughes, T., Agis, H., Fischer, T., Verhoef, G., Shepherd, J., Saglio, G., Gratwohl, A., Nielsen, J.L., Radich, J.P., Simonsson, B., Taylor, K., Baccarani, M., So, C., Letvak, L., Larson, R.A. N. Engl. J. Med. (2006) [Pubmed]
  4. Imatinib: paradigm or anomaly?. Druker, B.J. Cell. Cycle (2004) [Pubmed]
  5. Molecularly targeted therapy: have the floodgates opened?. Druker, B.J. Oncologist (2004) [Pubmed]
  6. Practical management of patients with chronic myeloid leukemia receiving imatinib. Deininger, M.W., O'Brien, S.G., Ford, J.M., Druker, B.J. J. Clin. Oncol. (2003) [Pubmed]
  7. Imatinib mesylate in the treatment of chronic myeloid leukaemia. Druker, B.J. Expert. Opin. Pharmacother (2003) [Pubmed]
  8. David A. Karnofsky Award lecture. Imatinib as a paradigm of targeted therapies. Druker, B.J. J. Clin. Oncol. (2003) [Pubmed]
  9. STI571 (Gleevec) as a paradigm for cancer therapy. Druker, B.J. Trends. Mol. Med (2002) [Pubmed]
  10. Perspectives on the development of a molecularly targeted agent. Druker, B.J. Cancer. Cell (2002) [Pubmed]
  11. Inhibition of the Bcr-Abl tyrosine kinase as a therapeutic strategy for CML. Druker, B.J. Oncogene (2002) [Pubmed]
  12. Imatinib and chronic myeloid leukemia: validating the promise of molecularly targeted therapy. Druker, B.J. Eur. J. Cancer (2002) [Pubmed]
  13. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. Druker, B.J., Talpaz, M., Resta, D.J., Peng, B., Buchdunger, E., Ford, J.M., Lydon, N.B., Kantarjian, H., Capdeville, R., Ohno-Jones, S., Sawyers, C.L. N. Engl. J. Med. (2001) [Pubmed]
  14. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. Druker, B.J., Sawyers, C.L., Kantarjian, H., Resta, D.J., Reese, S.F., Ford, J.M., Capdeville, R., Talpaz, M. N. Engl. J. Med. (2001) [Pubmed]
  15. Chronic myeloid leukemia. Sceptical scientists. Druker, B.J. Lancet (2001) [Pubmed]
  16. The role of the tyrosine kinase inhibitor STI571 in the treatment of cancer. O'Dwyer, M.E., Druker, B.J. Curr. Cancer. Drug. Targets (2001) [Pubmed]
WikiGenes - Universities